Video

Dr. Siddiqui on first-line treatments for bladder cancer

Author(s):

Urology Times staff
Conference|SUO Annual Meeting

“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.

In this video, Mohummad M. Siddiqui, MD, discusses the main takeaways concerning the bladder cancer therapeutics durvalumab (Imfinzi)/atezolizumab (Tecentriq) and pembrolizumab (Keytruda)/atezolizumab, which were topics focused on during the bladder cancer course presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Siddiqui is an associate professor of surgery and director of urologic oncology and robotic surgery at the University of Maryland, Baltimore.

Related Videos
Related Content
CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
February 20th 2025

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

Thomas E. Hutson, DO, PharmD
"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
February 18th 2025

Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

Hannah Clarke
However, the triplet regimen did not lead to an improvement in overall survival.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor
"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
February 15th 2025

Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

Benjamin P. Saylor
ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.
© 2025 MJH Life Sciences

All rights reserved.